Novo Nordisk stock target cut at Citi on lack of margin growth
Citi cut its price target on Novo Nordisk (NVO) to 296 DKK from 310 DKK, citing stable margins through 2030. Citi lowered its adjusted operating profit forecasts for 2028-2030 by 2-4% and reduced its expected EPS growth rate to 9% from 12%. However, Citi raised its 2026 and 2027 adjusted operating profit forecasts by 2-3% and lifted its adjusted sales forecasts. Novo plans to launch the Wegovy pill in 20 countries by the end of 2027.
How this was made
The 30-second read
Why it matters
The target cut reflects expectations of limited margin expansion, which could depress the stock despite higher sales forecasts for Wegovy.
Market read
Analyst downgrade for a major pharma name; may trigger short‑term sell pressure.
What to watch
Strong UK launch of Wegovy and expanding market reach could offset margin concerns over the longer term.
Background
Citi analysts reassessed Novo Nordisk's valuation after the company's CMD guidance showing stable margins and higher R&D spend.
Ticker impact
Citi Research cut Novo Nordisk's price target to 296 DKK, citing limited margin growth through 2030.
likely downside pressure as investors price in weaker margins
The target cut is a fresh, material analyst downgrade for a large‑cap pharma, which typically moves the stock on the day of release.
Market effects
May weigh on other GLP‑1 drug makers and broader pharma stocks as margin concerns spread.
European pharma indices could see modest pullback.
Limited to healthcare sector; no broad market impact.
Counterpoint
Citi raised 2026‑27 profit forecasts on higher Wegovy sales, suggesting upside if margin pressure eases.
Key entities
- companyNovo Nordisk
Danish pharmaceutical company developing obesity drugs.
- analyst_firmCiti Research
Equity research division that issued the price target revision.
